Clinical trials: Peripheral Vascular Response
Heart Disease, Heart Failure
Investigating Systemic and Local Vascular Responses to Apelin in the Context of Renin-angiotensin Upregulation
The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease.
- Conditions
- Heart Disease, Heart Failure, Vasodilatation
- Trial name
- NCT00901719
- Testing
- Apelin, Acetylcholine, Sodium nitroprusside
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Stroke
Peripheral Stimulation Neural Response
Few patients recover full hand dexterity after an acquired brain injury such as stroke. Repetitive somatosensory electrical stimulation (SES) is a promising method to promote recovery of hand function.
- Trial name
- NCT03176550
- Testing
- Transcutaneous electrical nerve stimulation
- Volunteers
- 8 people
- Sponsor
- University of California, San Francisco
Peripheral Arterial Disease
Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease
Cardiovascular disease remain one of the leading causes of death in Australia, accounting for 47637 (36%) of deaths in 2004. Peripheral arterial disease (PAD) is a category of cardiovascular disease, characterised by intermittent…
- Trial name
- NCT01871779
- Testing
- Standard Treadmill Exercise, Intermittent treadmill & resistance training
- Where
- Australia
- Volunteers
- 35 people
- Sponsor
- Flinders University
Fabry Disease
Dosing Study of Replagal in Patients With Fabry Disease
This study will determine the safety and effectiveness of increasing Replagal infusions in certain patients with Fabry disease. Replagal is a genetically engineered form of Alpha-galactosidase A, an enzyme that normally breaks…
- Trial name
- NCT00068107
- Testing
- Replagal
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Baylor Research Institute
Leukemia, Lymphoma
Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation
RATIONALE: Peripheral blood lymphocyte therapy may be effective in the treatment and prevention of Epstein-Barr virus infection following transplantation.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005606
- Testing
- allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes, autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
- Where
- United States
- Sponsor
- Northwestern University